Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
← catalyst calendarSponsored by VistaGen Therapeutics, Inc. (industry) · VTGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
238actual
Sites
26
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-16 | actual | When the study began enrolling |
| Primary completion | 2026-04-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Social Anxiety Disorder (SAD)
Interventions
- Drug: Fasedienol Nasal Spray
- Drug: Placebo Nasal Spray
Primary outcome
what the primary-completion date above is the date OFSubjective Units of Distress Scale (SUDS)
measured 7 days (Visit 2 to Visit 3)
Permalink · VTGN's whole pipeline · Catalyst calendar · Every registered study · What changed